Five Prime Announces Second Quarter 2016 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Five Prime Therapeutics (FRPX) PT Raised to $60 at Jefferies
August 5, 2016 9:51 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $60.00 (from $41.00) following Q2 results.
Yang commented, "Narrower 2Q net loss on higher revenue; estimated YE16 cash of ~$400M should fund operations into... More
Five Prime Therapeutics (FPRX) Tops Q2 EPS by 7c
August 4, 2016 5:38 PM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($0.49), $0.07 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $9.92 million versus the consensus estimate of $6.38 million.
"Were pleased with the progress weve made through the first half of the year and... More
